Loading...
Fuji Pharma Co., Ltd.
4554.T•JPX
Healthcare
Drug Manufacturers - Specialty & Generic
¥1392.00
¥-14.00(-1.00%)
Fuji Pharma Co., Ltd. (4554.T) Financial Performance & Income Statement Overview
Review Fuji Pharma Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
12.84%
↑ 12.84%
Operating Income Growth
0.57%
↑ 0.57%
Net Income Growth
78.92%
↑ 78.92%
Operating Cash Flow Growth
116.54%
↑ 116.54%
Operating Margin
9.71%
↑ 9.71%
Gross Margin
39.92%
↑ 39.92%
Net Profit Margin
6.50%
↑ 6.50%
ROE
6.90%
↑ 6.90%
ROIC
7.59%
↑ 7.59%
Fuji Pharma Co., Ltd. (4554.T) Income Statement & Financial Overview
Review Fuji Pharma Co., Ltd.'s (4554.T) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $13.00B | $12.98B | $11.77B | $10.64B |
| Cost of Revenue | $7.70B | $7.65B | $7.49B | $6.04B |
| Gross Profit | $5.30B | $5.33B | $4.28B | $4.60B |
| Gross Profit Ratio | $0.41 | $0.41 | $0.36 | $0.43 |
| R&D Expenses | $0.00 | $3.40B | $0.00 | $589.00M |
| SG&A Expenses | $4.05B | $1.06B | $3.51B | $2.42B |
| Operating Expenses | $4.05B | $3.67B | $3.51B | $3.01B |
| Total Costs & Expenses | $11.75B | $11.32B | $10.99B | $9.06B |
| Interest Income | $0.00 | $0.00 | $1.00M | $1.00M |
| Interest Expense | $0.00 | $0.00 | $54.00M | $43.00M |
| Depreciation & Amortization | $920.00M | $920.00M | $755.75M | $869.00M |
| EBITDA | $2.17B | $2.58B | $1.53B | $2.21B |
| EBITDA Ratio | $0.17 | $0.20 | $0.13 | $0.21 |
| Operating Income | $1.25B | $1.67B | $772.00M | $1.58B |
| Operating Income Ratio | $0.10 | $0.13 | $0.07 | $0.15 |
| Other Income/Expenses (Net) | $120.00M | -$210.00M | $20.00M | $588.00M |
| Income Before Tax | $1.37B | $1.46B | $792.00M | $2.17B |
| Income Before Tax Ratio | $0.11 | $0.11 | $0.07 | $0.20 |
| Income Tax Expense | $381.00M | $219.00M | $139.00M | $654.00M |
| Net Income | $991.00M | $1.24B | $653.00M | $1.52B |
| Net Income Ratio | $0.08 | $0.10 | $0.06 | $0.14 |
| EPS | $40.74 | $50.84 | $26.86 | $62.44 |
| Diluted EPS | $40.74 | $50.84 | $26.86 | $62.44 |
| Weighted Avg Shares Outstanding | $24.32M | $24.31M | $24.31M | $24.31M |
| Weighted Avg Shares Outstanding (Diluted) | $24.32M | $24.31M | $24.31M | $24.31M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan